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The Heart Team of Cardiovascular Care
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The management of complex cardiovascular disease has changed markedly with the development of new strate-
gies of care, an increasing amount of scientific evidence-based data and appropriate use criteria. Applying this
plethora of information and synthesizing it for presentation and recommendations to the patient and family
have assumed central importance. To facilitate this process of patient centric evidence-based care multidisci-
plinary Heart Teams have become identified as cornerstones. While specific strategies for implementation of
these teams will vary, this broad approach will become the standard of cardiovascular care. (J Am Coll Cardiol
2013;61:903–7) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1034The concept of a Heart Team has become the subject of
increasing interest in treating cardiovascular disease. While
a team-based approach has been part of the practice in other
medical fields such as oncology and is also a mainstay in
organ transplant programs, it has more recently been em-
phasized in treating cardiovascular disease. This emphasis
has been the result of the widespread attention given to the
concept in the SYNTAX (SYNergy Between PCI [percu-
taneous coronary intervention] With TAXUS and Cardiac
Surgery) trial (1–5) and now with the introduction of
transcatheter aortic valve replacement (TAVR) (6–12).
The rationale for team-based care is to optimize the
management of complex patient care issues, which has
become increasingly difficult because of the development of
new devices and approaches, the burgeoning amount of
scientific information on novel strategies both from ran-
domized clinical trials (RCTs) and large registries, and the
focus on patient groups at higher risk for adverse outcomes
because of advanced age or comorbidities. Although
evidence-based criteria for diagnostic and/or therapeutic
procedures have been emphasized, this approach remains
difficult even with use of appropriate criteria (13–20). While
recommendations based on these approaches make intu-
itive sense, they remain somewhat imprecise because of
the lack of specificity in accurate risk prediction for an
individual patient (21–25), as well as differing patient
expectations about those risks. The metrics on which
patients base their expectations vary widely; for example,
the expectations of a 92-year-old patient may be different
from those of a 65-year-old patient in terms of a
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such as death, myocardial infarction, stroke (either major
or minor), need for repeated procedures, or quality of life.
Such variation is a central component of the Institute of
Medicine priorities that care should be customized to the
patient’s needs and values and that the patient should be
the source of control.
The central goal of patient-centric care requires that the
patient and family be sufficiently educated about the alter-
natives available so that their expectations can be met as
fully as possible (26–28). Given the wide range of informa-
tion available from different cardiovascular specialties and
the potential for individual physician biases, team-based
care has great potential merit. This has now been codified in
guideline documents, and the Heart Team has emerged as a
class 1 indication in both the 2010 European Society of
Cardiology and the European Association for Cardio-
Thoracic Surgery Guidelines for Coronary Revasculariza-
tion (29) and the 2012 ACC/AHA Guidelines for Coro-
nary Artery Bypass Grafting surgery (16). The goal of the
multidisciplinary Heart Team is to offer a balanced and
complementary approach to patient care by joint and shared
decision making among different medical care stakeholders
such as cardiac surgery and interventional cardiology. By
exploring the multiple options available and sharing them
with patients and their families where applicable, more
optimal shared decision making is achieved, along with a
tailored recommendation for therapy for a more informed
and engaged patient. From a professional team point of
view, subsequent joint participation in procedures can not
only improve the skill sets of all involved medical and
surgical personnel but also elevate the cognitive interchange
that occurs among the specialties.
The importance of the Heart Team concept is typified
in two recent examples from the field of coronary
revascularization therapy and the newly approved proce-
dure of TAVR.
904 Holmes, Jr, et al. JACC Vol. 61, No. 9, 2013
The Heart Team of Cardiovascular Care March 5, 2013:903–7Coronary revascularization. A
plethora of data has accumulated
about the relative roles of percutane-
ous versus surgical revasculariza-
tion in the management of pa-
tients with complex coronary
artery disease (1,14,16,20–23,29,
30–32). It must be remembered
in this regard that either revascularization approach should be
layered against the fundamental backdrop of “optimal medical
therapy.”
In some clinical circumstances, the situation is
straightforward, for example, an acute coronary syndrome
with an isolated single discrete distal right coronary artery
stenosis in which PCI can be considered the treatment of
choice with little or no disagreement) or a patient with
significant angina, multiple coronary occlusions, and
other severe complex disease (with a high SYNTAX
score: 33) (1) with adequate target vessels and viable
myocardium in whom surgical revascularization is the
treatment of choice.
Many patients, however, fit between these two polar
opposites, and in this continuum, multiple considera-
tions exist. There is a burgeoning amount of information
from RCTs (e.g., the SYNTAX [1] and forthcoming
FREEDOM [Future Revascularization Evaluation in
Patients With Diabetes Mellitus: Optimal Management
of Multivessel Disease] [33] and EXCEL [Evaluation of
XIENCE PRIME Everolimus Eluting Stent System
{EECSS} or XIENCE V EECSS Versus Coronary Artery
Bypass Surgery for Effectiveness of Left Main Revascular-
ization] [34] trials), large-scale observational registry data
(e.g., the New York State trial [24]), and, most recently, the
largest and most robust data set from the National Heart,
Lung, and Blood Institute ASCERT [ACCF-STS Data-
base Collaboration on the Comparative Effectiveness of
Revascularization Strategies] trials (30,31,35), performed
jointly by investigators from the Society of Thoracic Sur-
geons and the American College of Cardiology. Outcome
data from both RCTs and registries are invaluable in
constructing as complete a picture as possible, although
each has advantages and disadvantages (Table 1). This is
complicated by the fact that there is often some degree of
discordance between the very carefully controlled RCTs
and the larger, more “real-world” registries. In addition,
the two revascularization strategies are markedly differ-
ent, each with its own risk-benefit ratios. Synthesizing
the information from the different data sets and strategies
is difficult. It is uncommon for any single trial to provide
the definitive answer for all patients in all settings, so
each data set must be evaluated as part of the whole picture.
The specific “truth” identified in each trial may be the result
of many factors, for example, patient population, method of
ascertainment of a specific endpoint (e.g., stroke), duration
of follow up, and adjunctive treatment; and other charac-
Abbreviations
and Acronyms
PCI  percutaneous
coronary intervention
TAVR  transcatheter
aortic valve replacementteristics as well as methodology of trial performance, qualityof data, robustness of the conclusions, and relevance to the
specific patient at hand must all be considered. In addition,
unmeasured confounding variables may potentially dramat-
ically alter conclusions. Although it is a common, perhaps
Revascularization Approachesfor Coron y Artery Dise seTable 1 Revascularization Approachesfor Coronary Artery Disease
CABG
Advantages Compared with PCI
Survival benefit in more complex disease particularly with left internal
mammary artery (LIMA) use
More complete revascularization
Reduction in subsequent myocardial infarction
Reduction in need for subsequent revascularization procedures
Disadvantages
More invasive
Longer recovery
Increased periprocedural stroke
Low use of multiple arterial grafts resulting in placement of venous conduits
with potential development of subsequent vein graft disease
Subsequent surgical procedures if needed are more difficult.
PCI
Advantages compared with CABG
Less Invasive
Treatment of focal ischemic producing lesions leaving other lesions for later
(targeted revascularization)
Shorter recovery
Can be repeated if needed
Patient preference
Disadvantages
Not shown to have a survival advantage or to decrease subsequent MI
outside of primary PCI
Less complete revascularization
Vascular access bleeding
Potential for stent thrombosis and need for dual antiplatelet therapy
May need to be repeated
Placement of very distal stents may preclude subsequent ability to place
surgical grafts
Hybrid coronary revascularization
Advantages
Minimally invasive
LIMA to LAD with long term survival benefit
Placement of DES rather than vein grafts to circumflex and right coronary artery
Heart Team approach
Completion angiography after surgery
Excellent choice in patients with limited conduit availability
Excellent choice in patients who have difficult to approach lesions with
traditional grafting (e.g., AV groove lesions with multiple branching small
epicardial coronary arteries subtending significant myocardial territories)
Disadvantages
Need for hybrid operation room/catheter laboratory or two procedures
Reimbursement issues
Still requires a surgical procedure
Not shown to have a survival advantage or to decrease subsequent MI
versus standard of care CABG when possible
No long-term randomized clinical trial data on relative safety/efficacy versus
conventional CABG
AV atrioventricular; CABG coronary artery bypass graft; DES drug-eluting stent(s); LAD left
anterior descending; LIMA  left internal mammary artery; MI  myocardial infarction; PCI 
percutaneous coronary intervention.universal, goal of patients to take the “least invasive”
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strategy, especially for the long-term outcome.
Implementation of a Heart Team can help to put these
issues into perspective for patients and their families. This
multidisciplinary team, including an experienced cardiac
surgeon, interventional cardiologist, and primary cardiolo-
gist, working together can help to focus on specific patient
considerations and expectations. This team can then evalu-
ate the specific clinical setting in the context of evolving data
from both RCTs and registries, as well as their individual
experience to fully inform the patient and family about the
risks/benefits ratio of any specific revascularization recom-
mendation. Combining first-hand patient expectations,
their consideration of hierarchical endpoints such as death,
myocardial infarction, stroke, and need for subsequent
procedures with available scientific data forms the basis for
personalized treatment recommendations.
Transcatheter aortic valve replacement. A second illus-
trative example of the central importance of the Heart Team
is in the treatment of severe aortic stenosis, which has been
transformed by the development of transcatheter ap-
proaches to aortic valve replacement compared to the
standard of care of surgical aortic valve replacement. More
than 50,000 TAVR procedures have been performed world-
wide (6–12,36). The scientific evidence available for these
two approaches comes in the form of multiple single-center,
multicenter, and national registries, as well as from one
RCT.
Available data indicate that: 1) many patients with severe
aortic stenosis are not offered traditional surgical aortic valve
replacement, either because of high or even prohibitive
surgical risk or patient preference; 2) in patients at prohib-
itive surgical risk, compared with standard medical therapy,
TAVR results in improved survival; 3) in patients at high
risk for surgical treatment but who are operable, TAVR
results in similar survival rates at 2 years of follow-up; and 4)
there are differences in risk profiles between surgical aortic
valve replacement and TAVR.
In the randomized PARTNER A (Placement of AoRTic
traNscathetER Valve) trial, although there was no signifi-
cant difference in mortality between the two groups, pa-
tients undergoing TAVR had an increase in periprocedural
strokes, both major and minor, at 30 days and at 1 year and
increased major vascular complications (37). On the other
hand, surgical AVR was associated with more major bleed-
ing and more atrial fibrillation. The conclusions were that
both approaches were acceptable in high-risk patients but
that there were different periprocedural hazards.
These essential but complex pieces of information must
be communicated to referring physicians and to patients and
their families in terms of patient selection and risk/benefit
ratio as well as procedural performance. This process has
been the focus of multiple expert consensus documents in
this field. These documents deal not only with patient
selection and procedural performance but also center andoperator credentialing and experience. A central component
of each of these documents has been the Heart Team.
In the case of TAVR, the Heart Team consists of the
cardiovascular surgeon, the interventional cardiologist, a
structural heart disease expert, and imaging specialists,
among others. This Heart Team approach has been recom-
mended by multiple specialty societies and is also mandated
by regulatory and reimbursement agencies including the
U.S. Food and Drug Administration and Centers for
Medicare and Medicaid Services based upon several issues
(6–8,38). These issues include the facts that there is already
an established surgical option, which has been tested over
the past 25 years; patients are elderly with multiple comor-
bidities, making any approach more complicated with
higher risks; consideration of TAVR includes evaluation of
peripheral arterial access and underlying coronary artery
disease, as well as the severity of the aortic stenosis and the
presence or absence of LV dysfunction; and, finally, proce-
dural performance improves when both cardiac surgeons
and interventional cardiologists perform the procedure to-
gether. This combination of facts including the risk/benefit
ratio of either surgical AVR, TAVR, or medical therapy
requires assessment by a multidisciplinary team to be com-
fortable with the recommendation to optimize patient care
and to educate the patient and the family.
As can be seen from the aforementioned examples, the
Heart Team has become an integral part of the practice of
modern cardiovascular care to optimize patient selection
through identification of the risk/benefit ratio of different
strategies, evaluation of the increasingly large and robust
data sets of both RCTs and observational registries, patient
and family education, and procedural performance and
follow-up.
Composition and implementation. The composition of
the Heart Team will vary depending on the specific clinical
situation and will also vary from institution to institution. In
the case of coronary revascularization, it should consist of
the cardiovascular surgeon, the interventional cardiologist
and the primary cardiologist, who is most familiar with the
nuances of the specific patient and family considerations. In
the case of TAVR, the team also will include consideration
of involvement of expert imaging specialists, neurologists,
vascular medicine physicians, and cardiac anesthesiologists,
all of whom are important in patient selection and proce-
dural performance.
Implementation of a Heart Team approach is not without
multiple potential issues and problems. From a logistical
standpoint, with current health care systems, work flow to
gather the Heart Team participants could become disrupted
and less efficient. In this regard, unavailability of particular
team members at any specific time may further disrupt the
process.
Establishing formats for interaction by the Heart Team
will be essential. In some institutions, there will the devel-
opment of a structural heart disease center to facilitate the
process (36). Such a dedicated center will include availability
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patient interaction and image assessment. There will also be
both print and video educational material for the patient
and family. This center will focus on patient evaluation,
selection, and education, with intensive efforts at discussion
of the risk/benefit ratio and alternative strategies of care.
In the case of coronary revascularization, a variety of
approaches has been undertaken. In some institutions,
patient cases with complex multivessel disease are presented
at a combined medical and surgical conference held weekly
or more often and the respective merits of specific ap-
proaches discussed, which can then be transmitted to the
patient by the primary cardiologist. In other institutions, the
system used in the SYNTAX trial may be implemented,
wherein the interventional cardiologist and cardiovascular
surgeon visit with the patient and the family together after
the diagnostic angiogram is obtained to discuss relative
advantages and disadvantages of each potential procedure
that could be performed so that the patient can be fully
informed.
There may be some instances in which the optimal
approach is straightforward and the Heart Team is not
needed. However, despite these challenges, approaches to
implementation must be developed. In the field of coronary
revascularization, for example, the application of PCI at the
time of diagnostic angiography in patients with complex or
multiple vessel disease will become more restricted. Instead,
patients will undergo diagnostic angiography in this setting,
and the procedure will be electively stopped to allow full
discussion with members of the Heart Team and the patient
and the family. This separation of diagnostic angiogram
from potential PCI will need to be discussed with the
patient and the family ahead of time and the importance of
it emphasized. Failure to implement a Heart Team is
increasingly not an option as the Heart Team is mandated
in certain clinical situations by societal guidelines, and
procedural reimbursement has been linked to it. Health
Care systems will need to evolve to include these health care
teams in optimizing patient-centered care.
Conclusions
Evolving strategies of care under some cardiovascular con-
ditions have identified the central role of the Heart Team in
optimizing patient selection, procedural performance, and
follow-up care and in enhancing the process of patient
education and informed consent. The composition of this
team may vary depending on the clinical setting and among
institutions. The Heart Team approach is timely and has
become mandatory in light of evolving options in therapeu-
tics, in the resurgence of focus on patient-centered care, and
for optimizing delivery of care and its reimbursement
strategies. The heart team concept forms the heart of
modern cardiovascular care.Reprint requests and correspondence: Dr. David R. Holmes, Jr.,
Mayo Clinic, Cardiovascular Diseases and Internal Medicine, 200
First Street, SWMB 4-523, Rochester, Minnesota 55905. E-mail:
holmes.david@mayo.edu.
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